Atria Investments’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.9M Buy
97,278
+8,391
+9% +$489K 0.07% 318
2025
Q4
$4.79M Sell
88,887
-16,957
-16% -$816K 0.05% 384
2025
Q3
$4.77M Sell
105,844
-13,959
-12% -$652K 0.05% 406
2025
Q2
$5.55M Sell
119,803
-42,976
-26% -$2.11M 0.07% 350
2025
Q1
$9.93M Sell
162,779
-20,375
-11% -$1.19M 0.13% 182
2024
Q4
$10.4M Buy
183,154
+55,296
+43% +$3.09M 0.13% 180
2024
Q3
$6.62M Buy
127,858
+10,911
+9% +$512K 0.08% 278
2024
Q2
$4.86M Sell
116,947
-21,891
-16% -$980K 0.06% 342
2024
Q1
$7.54M Buy
138,838
+16,270
+13% +$829K 0.1% 234
2023
Q4
$6.3M Sell
122,568
-21,995
-15% -$1.15M 0.1% 242
2023
Q3
$8.39M Sell
144,563
-15,716
-10% -$963K 0.15% 160
2023
Q2
$10.2M Buy
160,279
+7,402
+5% +$496K 0.19% 125
2023
Q1
$10.6M Buy
152,877
+19,862
+15% +$1.4M 0.2% 111
2022
Q4
$9.56M Sell
133,015
-141
-0.1% -$10.6K 0.2% 125
2022
Q3
$9.47M Sell
133,156
-4,429
-3% -$321K 0.21% 113
2022
Q2
$10.6M Sell
137,585
-2,995
-2% -$228K 0.22% 98
2022
Q1
$10.3M Buy
140,580
+26,188
+23% +$1.76M 0.18% 141
2021
Q4
$7.13M Buy
114,392
+18,779
+20% +$1.1M 0.13% 193
2021
Q3
$5.66M Buy
95,613
+2,914
+3% +$192K 0.1% 219
2021
Q2
$6.19M Sell
92,699
-3,417
-4% -$223K 0.12% 197
2021
Q1
$6.07M Buy
96,116
+985
+1% +$61.3K 0.13% 175
2020
Q4
$5.9M Sell
95,131
-16,488
-15% -$1.01M 0.14% 170
2020
Q3
$6.73M Buy
111,619
+19,057
+21% +$1.15M 0.2% 112
2020
Q2
$5.44M Buy
+92,562
New +$5.54M 0.19% 139
2020
Q1
Sell
-161,017
Closed -$10.3M 622
2019
Q4
$10.3M Buy
161,017
+112,445
+232% +$6.44M 0.28% 79
2019
Q3
$2.46M Sell
48,572
-5,349
-10% -$251K 0.09% 191
2019
Q2
$2.51M Buy
53,921
+18,948
+54% +$883K 0.09% 185
2019
Q1
$1.67M Buy
34,973
+8,334
+31% +$415K 0.07% 239
2018
Q4
$1.39M Sell
26,639
-26,625
-50% -$1.43M 0.06% 238
2018
Q3
$3.31M Buy
53,264
+1,202
+2% +$71.3K 0.13% 137
2018
Q2
$2.88M Sell
52,062
-703
-1% -$38K 0.13% 150
2018
Q1
$3.34M Buy
52,765
+4,204
+9% +$270K 0.16% 121
2017
Q4
$2.98M Buy
48,561
+7,094
+17% +$444K 0.15% 148
2017
Q3
$2.64M Buy
41,467
+748
+2% +$43.7K 0.14% 156
2017
Q2
$2.27M Sell
40,719
-142
-0.3% -$7.73K 0.14% 166
2017
Q1
$2.22M Buy
40,861
+5,349
+15% +$293K 0.14% 160
2016
Q4
$2.08M Buy
35,512
+5,387
+18% +$295K 0.16% 122
2016
Q3
$1.62M Buy
30,125
+1,636
+6% +$105K 0.15% 126
2016
Q2
$2.11M Buy
28,489
+4,788
+20% +$338K 0.23% 67
2016
Q1
$1.51M Sell
23,701
-2,661
-10% -$168K 0.17% 95
2015
Q4
$1.68M Buy
26,362
+2,293
+10% +$152K 0.18% 85
2015
Q3
$1.43M Sell
24,069
-4,177
-15% -$265K 0.2% 79
2015
Q2
$1.88M Sell
28,246
-1,522
-5% -$100K 0.22% 63
2015
Q1
$1.92M Buy
29,768
+843
+3% +$52.8K 0.22% 66
2014
Q4
$1.71M Buy
28,925
+2,798
+11% +$158K 0.18% 87
2014
Q3
$1.34M Buy
26,127
+938
+4% +$46.9K 0.14% 126
2014
Q2
$1.22M Buy
25,189
+1,774
+8% +$87.4K 0.12% 147
2014
Q1
$1.22M Buy
23,415
+1,635
+8% +$87K 0.12% 148
2013
Q4
$1.16M Buy
21,780
+8,049
+59% +$410K 0.12% 166
2013
Q3
$635K Buy
13,731
+3,411
+33% +$150K 0.07% 237
2013
Q2
$461K Buy
+10,320
New +$448K 0.06% 196

Other funds holding BMY

Atria Investments's BMY Position: Q1 2026 in Review

Atria Investments increased its Bristol-Myers Squibb (BMY) stake by 9.4% in Q1 2026, buying an estimated $489K and bringing the position to 97,278 shares worth $5.9M. The position accounts for 0.07% of the portfolio, ranked #318.

Atria Investments first reported a position in BMY in Q2 2013 and has held it in 51 quarters since. The position peaked at $10.6M in Q2 2022. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Atria Investments held 97,278 shares of Bristol-Myers Squibb worth $5.9M as of Q1 2026.
  • Atria Investments bought 8,391 Bristol-Myers Squibb shares in Q1 2026, an estimated $489K.
  • Bristol-Myers Squibb made up 0.07% of Atria Investments's portfolio in Q1 2026, its #318 holding.
  • Atria Investments first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 51 quarters since.
  • Atria Investments's Bristol-Myers Squibb position peaked at $10.6M in Q2 2022.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Atria Investments's 13F filing for Q1 2026, filed 5 May 2026.